{"transactions":[{"id":4635940,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":53362,"kind":"person","name":"Bowen Matthew","position":1,"cik":"0002115025","reported_name":"Bowen Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-10-06T20:05:05.000Z","date":"2026-10-05","kind":"sale","planned":false,"acquired":false,"shares":13,"price":10.56,"value":137.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":25891,"source":{"system":"sec-edgar","filing":"0001193125-26-415540","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2115025/000119312526415540/ownership.xml","form_type":"4"}},{"id":706955,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-07-17T20:05:04.000Z","date":"2026-07-16","kind":"sale","planned":false,"acquired":false,"shares":9500,"price":23.1809,"value":220218.55,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.18 to $23.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":585038,"source":{"system":"sec-edgar","filing":"0001193125-26-307791","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526307791/ownership.xml","form_type":"4"}},{"id":708212,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-16T20:10:42.000Z","date":"2026-07-15","kind":"exercise","planned":true,"acquired":false,"shares":4351,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":26947,"derivative":{"exercise_price":3.98,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":4351},"source":{"system":"sec-edgar","filing":"0001193125-26-306110","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526306110/ownership.xml","form_type":"4"}},{"id":708211,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-07-16T20:10:42.000Z","date":"2026-07-15","kind":"sale","planned":true,"acquired":false,"shares":4351,"price":23.3808,"value":101729.8608,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":62371,"source":{"system":"sec-edgar","filing":"0001193125-26-306110","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526306110/ownership.xml","form_type":"4"}},{"id":708210,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-07-16T20:10:42.000Z","date":"2026-07-15","kind":"exercise","planned":true,"acquired":true,"shares":4351,"price":3.98,"value":17316.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."}],"balance_after":66722,"source":{"system":"sec-edgar","filing":"0001193125-26-306110","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526306110/ownership.xml","form_type":"4"}},{"id":713704,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31723,"kind":"person","name":"Townson Sharon","position":1,"cik":"0001855689","reported_name":"Townson Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-07T20:41:28.000Z","date":"2026-07-06","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":197290,"derivative":{"exercise_price":6.14,"expiration_date":"2031-04-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001193125-26-297558","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1855689/000119312526297558/ownership.xml","form_type":"4"}},{"id":713703,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31723,"kind":"person","name":"Townson Sharon","position":1,"cik":"0001855689","reported_name":"Townson Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-07T20:41:28.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":400,"price":24.13,"value":9652.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."}],"balance_after":67845,"source":{"system":"sec-edgar","filing":"0001193125-26-297558","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855689/000119312526297558/ownership.xml","form_type":"4"}},{"id":713702,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31723,"kind":"person","name":"Townson Sharon","position":1,"cik":"0001855689","reported_name":"Townson Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-07T20:41:28.000Z","date":"2026-07-06","kind":"sale","planned":true,"acquired":false,"shares":5600,"price":23.2495,"value":130197.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.97 to $23.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":68245,"source":{"system":"sec-edgar","filing":"0001193125-26-297558","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855689/000119312526297558/ownership.xml","form_type":"4"}},{"id":713701,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31723,"kind":"person","name":"Townson Sharon","position":1,"cik":"0001855689","reported_name":"Townson Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-07T20:41:28.000Z","date":"2026-07-06","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":6.14,"value":36840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."}],"balance_after":73845,"source":{"system":"sec-edgar","filing":"0001193125-26-297558","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855689/000119312526297558/ownership.xml","form_type":"4"}},{"id":714466,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T21:57:07.000Z","date":"2026-07-01","kind":"other","planned":false,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"NEA Partners 17 made a distribution of 15,000 shares of Common Stock of the Issuer for no consideration on July 1, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, the sole general partner of NEA Partners 17, the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-296490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526296490/ownership.xml","form_type":"4"}},{"id":714465,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T21:57:07.000Z","date":"2026-07-01","kind":"other","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 4"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"NEA Partners 17 received 15,000 shares of Common Stock of the Issuer in the distribution made by NEA 17 on July 1, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a manager of NEA 17 GP, the sole general partner of NEA Partners 17, the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001193125-26-296490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526296490/ownership.xml","form_type":"4"}},{"id":714464,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-06T21:57:07.000Z","date":"2026-07-01","kind":"other","planned":false,"acquired":false,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"New Enterprise Associates 17, L.P. (\"NEA 17\") made a pro rata distribution of 1,000,000 shares of Common Stock of the Issuer to its general partner and limited partners for no consideration on July 1, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a manager of NEA 17 GP, LLC (\"NEA 17 GP\"), which is the sole general partner of NEA Partners 17, L.P. (\"NEA Partners 17\"). NEA Partners 17 is the sole general partner of NEA 17, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest."}],"balance_after":6692298,"source":{"system":"sec-edgar","filing":"0001193125-26-296490","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526296490/ownership.xml","form_type":"4"}},{"id":721393,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-01T20:57:48.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":5407,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":81093,"derivative":{"exercise_price":13.41,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":5407},"source":{"system":"sec-edgar","filing":"0001193125-26-292767","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526292767/ownership.xml","form_type":"4"}},{"id":721392,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:57:48.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":5407,"price":24.5,"value":132471.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."}],"balance_after":60612,"source":{"system":"sec-edgar","filing":"0001193125-26-292767","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526292767/ownership.xml","form_type":"4"}},{"id":721391,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:57:48.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":5407,"price":13.41,"value":72507.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 620 shares acquired under the Issuer's 2021 Employee Stock Purchase Program on June 30, 2026."}],"balance_after":66019,"source":{"system":"sec-edgar","filing":"0001193125-26-292767","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526292767/ownership.xml","form_type":"4"}},{"id":722910,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-30T20:05:37.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":60000,"derivative":{"exercise_price":7.56,"expiration_date":"2032-10-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001193125-26-290486","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526290486/ownership.xml","form_type":"4"}},{"id":722909,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-30T20:05:37.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":22.95,"value":137700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."}],"balance_after":59992,"source":{"system":"sec-edgar","filing":"0001193125-26-290486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526290486/ownership.xml","form_type":"4"}},{"id":722908,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-30T20:05:37.000Z","date":"2026-06-29","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":7.56,"value":45360.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."}],"balance_after":65992,"source":{"system":"sec-edgar","filing":"0001193125-26-290486","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526290486/ownership.xml","form_type":"4"}},{"id":722552,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34399,"kind":"person","name":"Manning Anthony M.","position":1,"cik":"0001716468","reported_name":"Manning Anthony M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-30T20:05:29.000Z","date":"2026-06-29","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":2100,"derivative":{"exercise_price":4.16,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193125-26-290484","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716468/000119312526290484/ownership.xml","form_type":"4"}},{"id":722551,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34399,"kind":"person","name":"Manning Anthony M.","position":1,"cik":"0001716468","reported_name":"Manning Anthony M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T20:05:29.000Z","date":"2026-06-29","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":23.11,"value":231100.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-290484","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716468/000119312526290484/ownership.xml","form_type":"4"}},{"id":722550,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34399,"kind":"person","name":"Manning Anthony M.","position":1,"cik":"0001716468","reported_name":"Manning Anthony M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T20:05:29.000Z","date":"2026-06-29","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":4.16,"value":41600.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001193125-26-290484","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716468/000119312526290484/ownership.xml","form_type":"4"}},{"id":726550,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T20:05:09.000Z","date":"2026-06-24","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":66000,"derivative":{"exercise_price":7.56,"expiration_date":"2032-10-03","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-26-282740","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526282740/ownership.xml","form_type":"4"}},{"id":726549,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T20:05:09.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":96000,"derivative":{"exercise_price":7.56,"expiration_date":"2032-10-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001193125-26-282740","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526282740/ownership.xml","form_type":"4"}},{"id":726548,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:05:09.000Z","date":"2026-06-24","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":21.4227,"value":642681.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.30 to $21.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":59992,"source":{"system":"sec-edgar","filing":"0001193125-26-282740","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526282740/ownership.xml","form_type":"4"}},{"id":726547,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:05:09.000Z","date":"2026-06-24","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":7.56,"value":226800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."}],"balance_after":89992,"source":{"system":"sec-edgar","filing":"0001193125-26-282740","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526282740/ownership.xml","form_type":"4"}},{"id":726546,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:05:09.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":11845,"price":20.2214,"value":239522.483,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":59992,"source":{"system":"sec-edgar","filing":"0001193125-26-282740","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526282740/ownership.xml","form_type":"4"}},{"id":726545,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:05:09.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":7.56,"value":45360.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026."}],"balance_after":71837,"source":{"system":"sec-edgar","filing":"0001193125-26-282740","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526282740/ownership.xml","form_type":"4"}},{"id":726683,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T20:05:04.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":false,"shares":2175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":31298,"derivative":{"exercise_price":3.98,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":2175},"source":{"system":"sec-edgar","filing":"0001193125-26-282735","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526282735/ownership.xml","form_type":"4"}},{"id":726682,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:05:04.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":2175,"price":20,"value":43500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."}],"balance_after":62371,"source":{"system":"sec-edgar","filing":"0001193125-26-282735","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526282735/ownership.xml","form_type":"4"}},{"id":726681,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:05:04.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":true,"shares":2175,"price":3.98,"value":8656.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."}],"balance_after":64546,"source":{"system":"sec-edgar","filing":"0001193125-26-282735","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526282735/ownership.xml","form_type":"4"}},{"id":726541,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31723,"kind":"person","name":"Townson Sharon","position":1,"cik":"0001855689","reported_name":"Townson Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T20:05:03.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option are fully vested and exercisable."}],"balance_after":203290,"derivative":{"exercise_price":6.14,"expiration_date":"2031-04-12","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001193125-26-282736","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855689/000119312526282736/ownership.xml","form_type":"4"}},{"id":726540,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31723,"kind":"person","name":"Townson Sharon","position":1,"cik":"0001855689","reported_name":"Townson Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:05:03.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":20,"value":60000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."}],"balance_after":67845,"source":{"system":"sec-edgar","filing":"0001193125-26-282736","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855689/000119312526282736/ownership.xml","form_type":"4"}},{"id":726539,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31723,"kind":"person","name":"Townson Sharon","position":1,"cik":"0001855689","reported_name":"Townson Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:05:03.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":true,"shares":3000,"price":6.14,"value":18420.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."}],"balance_after":70845,"source":{"system":"sec-edgar","filing":"0001193125-26-282736","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855689/000119312526282736/ownership.xml","form_type":"4"}},{"id":732387,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:05:07.000Z","date":"2026-06-17","kind":"exercise","planned":true,"acquired":false,"shares":2176,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":33473,"derivative":{"exercise_price":3.98,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":2176},"source":{"system":"sec-edgar","filing":"0001193125-26-275806","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526275806/ownership.xml","form_type":"4"}},{"id":732386,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-18T20:05:07.000Z","date":"2026-06-17","kind":"sale","planned":true,"acquired":false,"shares":2176,"price":19,"value":41344.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."}],"balance_after":62371,"source":{"system":"sec-edgar","filing":"0001193125-26-275806","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526275806/ownership.xml","form_type":"4"}},{"id":732385,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-18T20:05:07.000Z","date":"2026-06-17","kind":"exercise","planned":true,"acquired":true,"shares":2176,"price":3.98,"value":8660.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."}],"balance_after":64547,"source":{"system":"sec-edgar","filing":"0001193125-26-275806","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526275806/ownership.xml","form_type":"4"}},{"id":732238,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31723,"kind":"person","name":"Townson Sharon","position":1,"cik":"0001855689","reported_name":"Townson Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T20:05:06.000Z","date":"2026-06-17","kind":"exercise","planned":true,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested and exercisable."}],"balance_after":206290,"derivative":{"exercise_price":6.14,"expiration_date":"2031-04-12","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001193125-26-275805","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855689/000119312526275805/ownership.xml","form_type":"4"}},{"id":732237,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31723,"kind":"person","name":"Townson Sharon","position":1,"cik":"0001855689","reported_name":"Townson Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-18T20:05:06.000Z","date":"2026-06-17","kind":"sale","planned":true,"acquired":false,"shares":3000,"price":19,"value":57000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."}],"balance_after":67845,"source":{"system":"sec-edgar","filing":"0001193125-26-275805","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855689/000119312526275805/ownership.xml","form_type":"4"}},{"id":732236,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31723,"kind":"person","name":"Townson Sharon","position":1,"cik":"0001855689","reported_name":"Townson Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-18T20:05:06.000Z","date":"2026-06-17","kind":"exercise","planned":true,"acquired":true,"shares":3000,"price":6.14,"value":18420.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."}],"balance_after":70845,"source":{"system":"sec-edgar","filing":"0001193125-26-275805","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855689/000119312526275805/ownership.xml","form_type":"4"}},{"id":739172,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T22:44:45.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":25800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":25800,"derivative":{"exercise_price":17.1,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":25800},"source":{"system":"sec-edgar","filing":"0001193125-26-269885","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000119312526269885/ownership.xml","form_type":"4"}},{"id":739126,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34399,"kind":"person","name":"Manning Anthony M.","position":1,"cik":"0001716468","reported_name":"Manning Anthony M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:05:14.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":25800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":25800,"derivative":{"exercise_price":17.1,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":25800},"source":{"system":"sec-edgar","filing":"0001193125-26-269354","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716468/000119312526269354/ownership.xml","form_type":"4"}},{"id":739042,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:05:11.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":25800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":25800,"derivative":{"exercise_price":17.1,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":25800},"source":{"system":"sec-edgar","filing":"0001193125-26-269378","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526269378/ownership.xml","form_type":"4"}},{"id":740204,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":26426,"kind":"person","name":"Hughes Eric A","position":1,"cik":"0001938678","reported_name":"Hughes Eric A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T20:05:05.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":25800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":25800,"derivative":{"exercise_price":17.1,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":25800},"source":{"system":"sec-edgar","filing":"0001193125-26-269348","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1938678/000119312526269348/ownership.xml","form_type":"4"}},{"id":740361,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T16:05:29.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":25800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":25800,"derivative":{"exercise_price":17.1,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":25800},"source":{"system":"sec-edgar","filing":"0001193125-26-269365","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000119312526269365/ownership.xml","form_type":"4"}},{"id":740064,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":38783,"kind":"person","name":"Blackwell Kimberly","position":1,"cik":"0001816465","reported_name":"Blackwell Kimberly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T16:05:06.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":25800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":25800,"derivative":{"exercise_price":17.1,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":25800},"source":{"system":"sec-edgar","filing":"0001193125-26-269349","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816465/000119312526269349/ownership.xml","form_type":"4"}},{"id":739111,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":38522,"kind":"person","name":"Siu Christine","position":1,"cik":"0001743029","reported_name":"Siu Christine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T16:05:03.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":25800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":25800,"derivative":{"exercise_price":17.1,"expiration_date":"2036-06-11","underlying":"Common Stock","underlying_shares":25800},"source":{"system":"sec-edgar","filing":"0001193125-26-269368","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743029/000119312526269368/ownership.xml","form_type":"4"}},{"id":755091,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:05:24.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":468,"price":19.7262,"value":9231.8616,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.69 to $19.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":594538,"source":{"system":"sec-edgar","filing":"0001193125-26-253472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526253472/ownership.xml","form_type":"4"}},{"id":755090,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-06-02T20:05:24.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":4998,"price":19.412,"value":97021.176,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.69 to $19.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":595006,"source":{"system":"sec-edgar","filing":"0001193125-26-253472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526253472/ownership.xml","form_type":"4"}},{"id":757196,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31723,"kind":"person","name":"Townson Sharon","position":1,"cik":"0001855689","reported_name":"Townson Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-01T20:05:03.000Z","date":"2026-05-29","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option is fully vested and exercisable."}],"balance_after":209290,"derivative":{"exercise_price":6.14,"expiration_date":"2031-04-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001193125-26-251395","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855689/000119312526251395/ownership.xml","form_type":"4"}},{"id":757195,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31723,"kind":"person","name":"Townson Sharon","position":1,"cik":"0001855689","reported_name":"Townson Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-01T20:05:03.000Z","date":"2026-05-29","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":19.87,"value":119220.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.74 to $20.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":67845,"source":{"system":"sec-edgar","filing":"0001193125-26-251395","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855689/000119312526251395/ownership.xml","form_type":"4"}},{"id":757194,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31723,"kind":"person","name":"Townson Sharon","position":1,"cik":"0001855689","reported_name":"Townson Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-01T20:05:03.000Z","date":"2026-05-29","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":6.14,"value":36840.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026."}],"balance_after":73845,"source":{"system":"sec-edgar","filing":"0001193125-26-251395","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855689/000119312526251395/ownership.xml","form_type":"4"}},{"id":760438,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-28T23:10:37.000Z","date":"2026-05-27","kind":"exercise","planned":true,"acquired":false,"shares":2175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":35649,"derivative":{"exercise_price":3.98,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":2175},"source":{"system":"sec-edgar","filing":"0001193125-26-245728","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526245728/ownership.xml","form_type":"4"}},{"id":760437,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-28T23:10:37.000Z","date":"2026-05-27","kind":"sale","planned":true,"acquired":false,"shares":2175,"price":20,"value":43500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."}],"balance_after":62371,"source":{"system":"sec-edgar","filing":"0001193125-26-245728","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526245728/ownership.xml","form_type":"4"}},{"id":760436,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-28T23:10:37.000Z","date":"2026-05-27","kind":"exercise","planned":true,"acquired":true,"shares":2175,"price":3.98,"value":8656.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."}],"balance_after":64546,"source":{"system":"sec-edgar","filing":"0001193125-26-245728","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526245728/ownership.xml","form_type":"4"}},{"id":764110,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-26T20:05:04.000Z","date":"2026-05-22","kind":"exercise","planned":true,"acquired":false,"shares":2176,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":37824,"derivative":{"exercise_price":3.98,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":2176},"source":{"system":"sec-edgar","filing":"0001193125-26-239240","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526239240/ownership.xml","form_type":"4"}},{"id":764109,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:05:04.000Z","date":"2026-05-22","kind":"sale","planned":true,"acquired":false,"shares":2176,"price":19,"value":41344.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."}],"balance_after":62371,"source":{"system":"sec-edgar","filing":"0001193125-26-239240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526239240/ownership.xml","form_type":"4"}},{"id":764108,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-26T20:05:04.000Z","date":"2026-05-22","kind":"exercise","planned":true,"acquired":true,"shares":2176,"price":3.98,"value":8660.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026."}],"balance_after":64547,"source":{"system":"sec-edgar","filing":"0001193125-26-239240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526239240/ownership.xml","form_type":"4"}},{"id":765338,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34399,"kind":"person","name":"Manning Anthony M.","position":1,"cik":"0001716468","reported_name":"Manning Anthony M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T20:05:09.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option are fully vested and exercisable."}],"balance_after":12100,"derivative":{"exercise_price":4.16,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193125-26-236840","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1716468/000119312526236840/ownership.xml","form_type":"4"}},{"id":765337,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34399,"kind":"person","name":"Manning Anthony M.","position":1,"cik":"0001716468","reported_name":"Manning Anthony M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-22T20:05:09.000Z","date":"2026-05-21","kind":"sale","planned":false,"acquired":false,"shares":10000,"price":18.01,"value":180100.0,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-236840","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1716468/000119312526236840/ownership.xml","form_type":"4"}},{"id":765336,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34399,"kind":"person","name":"Manning Anthony M.","position":1,"cik":"0001716468","reported_name":"Manning Anthony M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-22T20:05:09.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":true,"shares":10000,"price":4.16,"value":41600.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001193125-26-236840","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716468/000119312526236840/ownership.xml","form_type":"4"}},{"id":791862,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-05-05T20:05:03.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":5467,"price":18.922,"value":103446.574,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.67 to $19.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":600004,"source":{"system":"sec-edgar","filing":"0001193125-26-206344","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526206344/ownership.xml","form_type":"4"}},{"id":808216,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-04-15T20:05:02.000Z","date":"2026-04-14","kind":"sale","planned":false,"acquired":false,"shares":8000,"price":17.6406,"value":141124.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.64 to $17.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":605471,"source":{"system":"sec-edgar","filing":"0001193125-26-156981","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526156981/ownership.xml","form_type":"4"}},{"id":810098,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":52828,"kind":"person","name":"Nickson Philip","position":1,"cik":"0001911369","reported_name":"Nickson Philip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Legal Officer"}}],"security":"Common Stock","published_at":"2026-04-10T20:07:54.000Z","date":"2026-04-09","kind":"sale","planned":false,"acquired":false,"shares":5845,"price":17.6925,"value":103412.6625,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.6901 to $17.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":55000,"source":{"system":"sec-edgar","filing":"0001193125-26-151254","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526151254/ownership.xml","form_type":"4"}},{"id":813085,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":53362,"kind":"person","name":"Bowen Matthew","position":1,"cik":"0002115025","reported_name":"Bowen Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-07T20:10:03.000Z","date":"2026-04-06","kind":"grant","planned":false,"acquired":true,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of this option shall vest and become exercisable on April 6, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":19500,"derivative":{"exercise_price":16.93,"expiration_date":"2036-04-05","underlying":"Common Stock","underlying_shares":19500},"source":{"system":"sec-edgar","filing":"0001193125-26-145545","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526145545/ownership.xml","form_type":"4"}},{"id":813084,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":53362,"kind":"person","name":"Bowen Matthew","position":1,"cik":"0002115025","reported_name":"Bowen Matthew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-04-07T20:10:03.000Z","date":"2026-04-06","kind":"grant","planned":false,"acquired":true,"shares":4300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on April 6, 2027, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":25904,"source":{"system":"sec-edgar","filing":"0001193125-26-145545","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526145545/ownership.xml","form_type":"4"}},{"id":858898,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":62597,"kind":"person","name":"Dunn Edmund","position":1,"cik":"0001989401","reported_name":"Dunn Edmund","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-03-05T22:24:23.000Z","date":"2026-03-04","kind":"sale","planned":false,"acquired":false,"shares":139,"price":17.96,"value":2496.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."}],"balance_after":22554,"source":{"system":"sec-edgar","filing":"0001193125-26-094296","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1989401/000119312526094296/ownership.xml","form_type":"4"}},{"id":861913,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-03-04T21:50:05.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":5466,"price":17.9243,"value":97974.2238,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $18.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":613471,"source":{"system":"sec-edgar","filing":"0001193125-26-091733","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526091733/ownership.xml","form_type":"4"}},{"id":874667,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":62597,"kind":"person","name":"Dunn Edmund","position":1,"cik":"0001989401","reported_name":"Dunn Edmund","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-02T22:02:46.000Z","date":"2026-03-02","kind":"exercise","planned":false,"acquired":false,"shares":536,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":13.41,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":536},"source":{"system":"sec-edgar","filing":"0001193125-26-085677","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1989401/000119312526085677/ownership.xml","form_type":"4"}},{"id":874666,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":62597,"kind":"person","name":"Dunn Edmund","position":1,"cik":"0001989401","reported_name":"Dunn Edmund","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-02T22:02:46.000Z","date":"2026-02-27","kind":"exercise","planned":false,"acquired":false,"shares":25164,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested and exercisable."}],"balance_after":536,"derivative":{"exercise_price":13.41,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":25164},"source":{"system":"sec-edgar","filing":"0001193125-26-085677","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1989401/000119312526085677/ownership.xml","form_type":"4"}},{"id":874665,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":62597,"kind":"person","name":"Dunn Edmund","position":1,"cik":"0001989401","reported_name":"Dunn Edmund","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-03-02T22:02:46.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":536,"price":17.5,"value":9380.0,"ownership":{"direct":true},"balance_after":22693,"source":{"system":"sec-edgar","filing":"0001193125-26-085677","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1989401/000119312526085677/ownership.xml","form_type":"4"}},{"id":874664,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":62597,"kind":"person","name":"Dunn Edmund","position":1,"cik":"0001989401","reported_name":"Dunn Edmund","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-03-02T22:02:46.000Z","date":"2026-03-02","kind":"exercise","planned":false,"acquired":true,"shares":536,"price":13.41,"value":7187.76,"ownership":{"direct":true},"balance_after":23229,"source":{"system":"sec-edgar","filing":"0001193125-26-085677","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1989401/000119312526085677/ownership.xml","form_type":"4"}},{"id":874663,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":62597,"kind":"person","name":"Dunn Edmund","position":1,"cik":"0001989401","reported_name":"Dunn Edmund","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-03-02T22:02:46.000Z","date":"2026-02-27","kind":"sale","planned":false,"acquired":false,"shares":25164,"price":18.1015,"value":455506.146,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.06 to $18.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":22693,"source":{"system":"sec-edgar","filing":"0001193125-26-085677","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1989401/000119312526085677/ownership.xml","form_type":"4"}},{"id":874662,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":62597,"kind":"person","name":"Dunn Edmund","position":1,"cik":"0001989401","reported_name":"Dunn Edmund","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-03-02T22:02:46.000Z","date":"2026-02-27","kind":"exercise","planned":false,"acquired":true,"shares":25164,"price":13.41,"value":337449.24,"ownership":{"direct":true},"balance_after":47857,"source":{"system":"sec-edgar","filing":"0001193125-26-085677","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1989401/000119312526085677/ownership.xml","form_type":"4"}},{"id":885228,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-24T21:05:11.000Z","date":"2026-02-23","kind":"sale","planned":false,"acquired":false,"shares":9189,"price":19.4973,"value":179160.6897,"ownership":{"direct":true},"balance_after":65837,"source":{"system":"sec-edgar","filing":"0001193125-26-066955","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526066955/ownership.xml","form_type":"4"}},{"id":942268,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-09T21:05:17.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":309,"price":24.5736,"value":7593.2424,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.43 to $24.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":618937,"source":{"system":"sec-edgar","filing":"0001193125-26-008902","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526008902/ownership.xml","form_type":"4"}},{"id":942267,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-09T21:05:17.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":1450,"price":23.8762,"value":34620.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.43 to $24.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":619246,"source":{"system":"sec-edgar","filing":"0001193125-26-008902","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526008902/ownership.xml","form_type":"4"}},{"id":942266,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-09T21:05:17.000Z","date":"2026-01-07","kind":"sale","planned":true,"acquired":false,"shares":3707,"price":23.2422,"value":86158.8354,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.42 to $23.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":620696,"source":{"system":"sec-edgar","filing":"0001193125-26-008902","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526008902/ownership.xml","form_type":"4"}},{"id":949743,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":52828,"kind":"person","name":"Nickson Philip","position":1,"cik":"0001911369","reported_name":"Nickson Philip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:06:08.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":126000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of this option shall vest and become exercisable on January 2, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":126000,"derivative":{"exercise_price":15.31,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":126000},"source":{"system":"sec-edgar","filing":"0001193125-26-002406","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526002406/ownership.xml","form_type":"4"}},{"id":949742,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":52828,"kind":"person","name":"Nickson Philip","position":1,"cik":"0001911369","reported_name":"Nickson Philip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Legal Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:06:08.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":3155,"price":15.17,"value":47861.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.17 to $15.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":60845,"source":{"system":"sec-edgar","filing":"0001193125-26-002406","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526002406/ownership.xml","form_type":"4"}},{"id":949741,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":52828,"kind":"person","name":"Nickson Philip","position":1,"cik":"0001911369","reported_name":"Nickson Philip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business & Legal Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:06:08.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":28000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 2, 2027, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":64000,"source":{"system":"sec-edgar","filing":"0001193125-26-002406","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526002406/ownership.xml","form_type":"4"}},{"id":952215,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:05:21.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":158000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of this option shall vest and become exercisable on January 2, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":158000,"derivative":{"exercise_price":15.31,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":158000},"source":{"system":"sec-edgar","filing":"0001193125-26-002401","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526002401/ownership.xml","form_type":"4"}},{"id":952214,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:05:21.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":2629,"price":15.17,"value":39881.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.17 to $15.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":62371,"source":{"system":"sec-edgar","filing":"0001193125-26-002401","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526002401/ownership.xml","form_type":"4"}},{"id":952213,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":30117,"kind":"person","name":"Champoux Jennifer","position":1,"cik":"0002025233","reported_name":"Champoux Jennifer","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:05:21.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 2, 2027, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":65000,"source":{"system":"sec-edgar","filing":"0001193125-26-002401","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2025233/000119312526002401/ownership.xml","form_type":"4"}},{"id":952131,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":62597,"kind":"person","name":"Dunn Edmund","position":1,"cik":"0001989401","reported_name":"Dunn Edmund","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:04:58.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":1039,"price":15.17,"value":15761.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.17 to $15.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":22693,"source":{"system":"sec-edgar","filing":"0001193125-26-002390","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1989401/000119312526002390/ownership.xml","form_type":"4"}},{"id":951855,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:04:37.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":406000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of this option shall vest and become exercisable on January 2, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":406000,"derivative":{"exercise_price":15.31,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":406000},"source":{"system":"sec-edgar","filing":"0001193125-26-002389","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526002389/ownership.xml","form_type":"4"}},{"id":951854,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-05T21:04:37.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":10135,"price":15.17,"value":153747.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.17 to $15.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":624403,"source":{"system":"sec-edgar","filing":"0001193125-26-002389","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526002389/ownership.xml","form_type":"4"}},{"id":951853,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":29778,"kind":"person","name":"Warmuth Markus","position":1,"cik":"0001855643","reported_name":"Warmuth Markus","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Common Stock","published_at":"2026-01-05T21:04:37.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 2, 2027, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":634538,"source":{"system":"sec-edgar","filing":"0001193125-26-002389","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855643/000119312526002389/ownership.xml","form_type":"4"}},{"id":951880,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:04:31.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":139000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of this option shall vest and become exercisable on January 2, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":139000,"derivative":{"exercise_price":15.31,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":139000},"source":{"system":"sec-edgar","filing":"0001193125-26-002386","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526002386/ownership.xml","form_type":"4"}},{"id":951879,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:04:31.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":3155,"price":15.17,"value":47861.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.17 to $15.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":75026,"source":{"system":"sec-edgar","filing":"0001193125-26-002386","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526002386/ownership.xml","form_type":"4"}},{"id":951878,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34039,"kind":"person","name":"Janku Filip","position":1,"cik":"0001862930","reported_name":"Janku Filip","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:04:31.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":31000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 2, 2027, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,992 shares acquired under the Issuer's 2021 Employee Stock Purchase Program on December 31, 2025."}],"balance_after":78181,"source":{"system":"sec-edgar","filing":"0001193125-26-002386","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1862930/000119312526002386/ownership.xml","form_type":"4"}},{"id":951852,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31723,"kind":"person","name":"Townson Sharon","position":1,"cik":"0001855689","reported_name":"Townson Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:04:07.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":158000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of this option shall vest and become exercisable on January 2, 2027, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":158000,"derivative":{"exercise_price":15.31,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":158000},"source":{"system":"sec-edgar","filing":"0001193125-26-002385","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1855689/000119312526002385/ownership.xml","form_type":"4"}},{"id":951851,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31723,"kind":"person","name":"Townson Sharon","position":1,"cik":"0001855689","reported_name":"Townson Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:04:07.000Z","date":"2026-01-05","kind":"sale","planned":false,"acquired":false,"shares":3155,"price":15.17,"value":47861.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.17 to $15.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder\nof the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":67845,"source":{"system":"sec-edgar","filing":"0001193125-26-002385","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1855689/000119312526002385/ownership.xml","form_type":"4"}},{"id":951850,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31723,"kind":"person","name":"Townson Sharon","position":1,"cik":"0001855689","reported_name":"Townson Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:04:07.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":35000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 25% of the RSUs shall vest on January 2, 2027, with the remainder vesting in 3 equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":71000,"source":{"system":"sec-edgar","filing":"0001193125-26-002385","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1855689/000119312526002385/ownership.xml","form_type":"4"}},{"id":1109409,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":31983,"kind":"person","name":"Behbahani Ali","position":1,"cik":"0001613867","reported_name":"Behbahani Ali","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:10:47.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":30700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":30700,"derivative":{"exercise_price":4.91,"expiration_date":"2035-06-13","underlying":"Common Stock","underlying_shares":30700},"source":{"system":"sec-edgar","filing":"0000950170-25-086727","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1613867/000095017025086727/ownership.xml","form_type":"4"}},{"id":1110002,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":26426,"kind":"person","name":"Hughes Eric A","position":1,"cik":"0001938678","reported_name":"Hughes Eric A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:05:11.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":30700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":30700,"derivative":{"exercise_price":4.91,"expiration_date":"2035-06-13","underlying":"Common Stock","underlying_shares":30700},"source":{"system":"sec-edgar","filing":"0000950170-25-086704","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1938678/000095017025086704/ownership.xml","form_type":"4"}},{"id":1109392,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":34399,"kind":"person","name":"Manning Anthony M.","position":1,"cik":"0001716468","reported_name":"Manning Anthony M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:05:10.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":30700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":30700,"derivative":{"exercise_price":4.91,"expiration_date":"2035-06-13","underlying":"Common Stock","underlying_shares":30700},"source":{"system":"sec-edgar","filing":"0000950170-25-086703","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1716468/000095017025086703/ownership.xml","form_type":"4"}},{"id":1109329,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T20:05:04.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":30700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":30700,"derivative":{"exercise_price":4.91,"expiration_date":"2035-06-13","underlying":"Common Stock","underlying_shares":30700},"source":{"system":"sec-edgar","filing":"0000950170-25-086700","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1826457/000095017025086700/ownership.xml","form_type":"4"}},{"id":1109866,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":38783,"kind":"person","name":"Blackwell Kimberly","position":1,"cik":"0001816465","reported_name":"Blackwell Kimberly","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T16:05:08.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":30700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":30700,"derivative":{"exercise_price":4.91,"expiration_date":"2035-06-13","underlying":"Common Stock","underlying_shares":30700},"source":{"system":"sec-edgar","filing":"0000950170-25-086702","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816465/000095017025086702/ownership.xml","form_type":"4"}},{"id":1109380,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":38522,"kind":"person","name":"Siu Christine","position":1,"cik":"0001743029","reported_name":"Siu Christine","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T16:05:06.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":30700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":30700,"derivative":{"exercise_price":4.91,"expiration_date":"2035-06-13","underlying":"Common Stock","underlying_shares":30700},"source":{"system":"sec-edgar","filing":"0000950170-25-086701","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1743029/000095017025086701/ownership.xml","form_type":"4"}},{"id":1110152,"issuer":{"id":4828,"kind":"organization","name":"Monte Rosa Therapeutics, Inc.","symbol":"GLUE"},"owners":[{"id":38918,"kind":"person","name":"SCHIFF ANDREW N","position":1,"cik":"0001172252","reported_name":"SCHIFF ANDREW N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-16T16:05:03.000Z","date":"2025-06-13","kind":"grant","planned":false,"acquired":true,"shares":30700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 13, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time."}],"balance_after":30700,"derivative":{"exercise_price":4.91,"expiration_date":"2035-06-13","underlying":"Common Stock","underlying_shares":30700},"source":{"system":"sec-edgar","filing":"0000950170-25-086699","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1172252/000095017025086699/ownership.xml","form_type":"4"}}],"next_cursor":"2025-06-16T16:05:03.000000Z,1110152"}